Who Paid My Doc
Michael Birrer
Hematology & Oncology Birmingham, AL Medical Doctor
NPI 1164643714 CMS profile 52479
619 19Th St S, Birmingham, AL 35249
General payments
$301,845
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$765,662
Through program year 2025, Michael Birrer of Birmingham, AL is reported in the CMS Open Payments database as having received $301,845 across 277 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $765,662 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $13,820 | 20 | |
| 2024 | General | $16,581 | 20 | |
| 2023 | General | $20,434 | 24 | |
| 2022 | General | $22,174 | 35 | |
| 2021 | General | $42,715 | 28 | |
| 2020 | General | $59,908 | 37 | |
| 2019 | General | $126,213 | 113 |
Beside peers
- Michael Birrer
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Michael Birrer were reported at $13,820. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Michael Birrer | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $126,213 | $529 | $121–$2,516 | $163 |
| 2020 | $59,908 | $339 | $82–$2,213 | $114 |
| 2021 | $42,715 | $263 | $49–$1,965 | $132 |
| 2022 | $22,174 | $416 | $103–$2,395 | $149 |
| 2023 | $20,434 | $542 | $125–$2,646 | $160 |
| 2024 | $16,581 | $692 | $141–$3,008 | $164 |
| 2025 | $13,820 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
277 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Alabama
Amitkumar Mehta
Hematology & Oncology · Birmingham, AL
Pankit Vachhani
Hematology & Oncology · Birmingham, AL
Luciano Costa
Hematology & Oncology · Birmingham, AL
Khaleel Ashraf
Hematology & Oncology · Birmingham, AL
Rudolph Navari
Hematology & Oncology · Birmingham, AL
Mayur Narkhede
Hematology & Oncology · Birmingham, AL
Related records
Hematology & Oncology in Alabama
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Alabama
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.